Exogenously administered IL-33 increased the expression of alarmins, Th2 chemokines (CCL17 and CCL22), CD8 + T cell chemokines (CXCL10, CX3CL1), eosinophil chemokines (CCL11, CCL13, CCL24), as well as Th2-related cytokines (IL-4, IL-13) and Th1 effector molecules (granzyme B) in the primary tumor. The gene discussed is IL33; the disease is neoplasm.